返回 Agenda
[V4-S3] What is the Role of Medical Science Liaison (MSL) as New Function of Pharmaceutical Company?
Session Chair(s)
Koji Iwasaki, PHD
Professor, Academic Clinical Research Center, , Osaka University Hospital, Japan
The pharmaceutical companies are starting to establish medical science liaison (MSL) as the new type of job to assume and exchange medical scientific information. In this session, we will discuss an appropriate profit of the drug information about an activity of MSLs In addition to catch the situation of MSL activities in the pharmaceutical company, we will clarify recognition of MSLs by Academia and MHLW. And then we discuss around the future appropriate drug information and the talent of MSLs.
Speaker(s)
Masaru Iwasaki, MD, PHD
Vice President, Head of Center for Advancing Clinical Research (CACR), University of Yamanashi, Japan
The Role of MSL - Expectation from Academia -
Yoshihiko Otoguro
Corporate Ethics Working Group, Governance and Legal Committee, European Federation of Pharmaceutical Industries and Associations, Japan
The Positioning and Activity Principles of MSL -EFPIA Japan-
Michiko Tomiyasu
Manager, Medical Affairs, Sanofi K.K., Japan
MSL: Their Role and What They Should be Equipped for
Yoshifumi Banzai, PHD
Deputy Director, Compliance and Narcotics Division, Ministry of Health, Labour and Welfare (MHLW), Japan
Expectation to Medical Science Liaison (MSL) in the Utilization of Drug Information from Regulatory Authorities